サポート ブログ Personalized Antibody Therapies

Personalized Antibody Therapies

Biointron 2024-01-26
Personalized Medicine.jpg
Image credit: DOI: 10.1134/S0361768821080284

Personalized medicine, also known as individualized medicine, is a medical approach that tailors treatment to the individual characteristics of each patient. Precision medicine is similar but stratifies therapies for subgroups of patients who possess, for instance, a genetic variant of interest. It takes into account both your genetic and environmental factors for the development of diagnostic, prognostic, and therapeutic strategies. This personalization allows it to be particularly applicable to cancer, as tumors tend to arise from genetic variants.1,2

Antibody drugs are suitable as personalized medicine due to their high specificity. Monoclonal antibodies (mAbs) can be designed to target specific antigens and have been indicated for several tumors, in addition to being used in diagnostic tools to identify the source of a tumor. mAbs may be associated to biomarkers such as HER2, KRAS, or PD-L1, which are molecules in the body that can be used to signal normal or abnormal activity in a patient.

Currently, target prioritization is still a challenge for personalization, as there are relatively few biomarkers. Those that have been reported for mAb drugs, are typically the same ones. Garattini and Padula (2019) report a tendency to treat cancer tumors with different sites of origin with combination therapies instead of developing therapies encompassing a single cancer.

Another area where mAbs can be useful as personalized medicine is inflammatory bowel disease (IBD). Traditional therapies for IBDs such as Crohn's disease and ulcerative colitis are based on aminosalicylates, antimetabolites, and immunosuppressants. However, therapeutic effectiveness varies in patients, leading to a search for more personalized treatments, such as mAbs, which have ideal pharmacokinetic characteristics. This includes a relatively small volume of distribution, a clearance depending on many activities, a minimal renal excretion, and the presence of antidrug antibodies.3

Besides mAbs, antibody-drug conjugates (ADCs) represent a fast-growing area of therapeutics. ADCs combine the specificity of mAbs with a cytotoxic (cell-killing) payload through covalent bonds. In cancer, this approach aims to deliver chemotherapy directly to cancer cells via specific binding to cell surface receptors on a solid tumor, while minimizing damage to normal, healthy cells. Since the level of target expression is a main factor in anticipating the ADC’s benefit for patients, establishing a patient selection strategy is important for a personalized approach.4


At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


References:

  1. Garattini, L., & Padula, A. (2019). Precision medicine and monoclonal antibodies: Breach of promise? Croatian Medical Journal, 60(3), 284-289. https://doi.org/10.3325/cmj.2019.60.284

  2. Jain, K. K. (2021). Personalized Immuno-Oncology. Medical Principles and Practice, 30(1), 1-16. https://doi.org/10.1159/000511107

  3. Di Paolo, A., & Luci, G. (2021). Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Frontiers in Pharmacology, 11, 610806. https://doi.org/10.3389/fphar.2020.610806

  4. Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023). Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers, 15(15). https://doi.org/10.3390/cancers15153886

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。